Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2012 1
2018 1
2019 1
2020 2
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze SM, Van Tine BA, Coleman RL, Knoblauch R, Triantos S, Hu P, Shalaby W, McGowan T, Monk BJ, Demetri GD. Jones RL, et al. Among authors: shalaby w. Cancer Med. 2021 Jun;10(11):3565-3574. doi: 10.1002/cam4.3903. Epub 2021 May 7. Cancer Med. 2021. PMID: 33960681 Free PMC article.
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. Monk BJ, et al. Among authors: shalaby wsw. Gynecol Oncol. 2020 Mar;156(3):535-544. doi: 10.1016/j.ygyno.2019.12.043. Epub 2020 Jan 8. Gynecol Oncol. 2020. PMID: 31924332 Clinical Trial.
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. Monk BJ, et al. Among authors: shalaby wsw. Data Brief. 2020 Mar 20;30:105465. doi: 10.1016/j.dib.2020.105465. eCollection 2020 Jun. Data Brief. 2020. PMID: 32346557 Free PMC article.
Development of novel substrates for tumor immunotherapy.
Shalaby WS, Yeh H, Woo E, Hendren S, Corbett JT, Gray H, June CH, Shalaby SW. Shalaby WS, et al. J Control Release. 2003 Aug 28;91(1-2):209-24. doi: 10.1016/s0168-3659(03)00238-4. J Control Release. 2003. PMID: 12932653